University of Rome Tor Vergata
uniroma2.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
90
Active
12
Phase 3
8
Total enrollment
329,069
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Circulating tumour DNA levels assessment | — | — | — | — | — | 1 | |
| letermovir prophylaxis | — | — | — | — | — | 1 | |
| MR-proADM dosage | — | — | — | — | — | 1 |
Next readouts
- 2026-05-01
- 2027-09-30
- 2028-08-15
Top conditions
- Surgery4
- Colon Cancer4
- Heart Failure4
- Breast Cancer3
- Morbid Obesity3
- Anastomotic Leak2
- Bladder Cancer2
- Metabolic Syndrome2
Frequently asked questions about University of Rome Tor Vergata
- How many clinical trials does University of Rome Tor Vergata have on ClinicalTrials.gov?
- University of Rome Tor Vergata is listed as the lead sponsor on 90 clinical trials in ClinicalTrials.gov, 12 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Rome Tor Vergata's trials are in Phase 3?
- 8 of University of Rome Tor Vergata's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Rome Tor Vergata focus on?
- University of Rome Tor Vergata's most-studied conditions on ClinicalTrials.gov are Surgery, Colon Cancer, Heart Failure, Breast Cancer, Morbid Obesity.
- When are University of Rome Tor Vergata's next clinical trial readouts?
- University of Rome Tor Vergata has 3 upcoming primary-completion readouts tracked here; the soonest is “MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation”, expected around 2026-05-01.